The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

  title={The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.},
  author={Jack M Lawrence and Gideon Meyerowitz-Katz and James A. J. Heathers and Nicholas J L Brown and Kyle Sheldrick},
  journal={Nature medicine},
To the Editor — The global demand for prophylactic and treatment options for COVID-19 has in turn created a demand for both randomized clinical trials, and the synthesis of those trials into meta-analyses by systematic review. This process has been fraught, and has demonstrated the inherent risks in current approaches and accepted standards of quantitative evidence synthesis when dealing with high volumes of recent, often unpublished trial data of variable quality. Research into the use of… 
Signals were broadly positive for months, but never definitive: the tocilizumab story
Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis
Evidence supports that strongyloidiasis prevalence interacts with the RR of mortality in ivermectin trial results; no evidence was found to suggest iver mectin has any role in preventing mortality in patients with COVID-19 in regions where strongyloidsiasis is not endemic.
Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model
Ivermectin monotherapy did not reduce lung viral load and even significantly worsened the SARS-CoV-2-induced lung pathology and it did not potentiate the activity of Molnupiravir (Lagevrio™) when combined with this drug.
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
Ivermectin monotherapy did not reduce lung viral load and even significantly worsened SARS-CoV-2-induced lung pathology and it did not potentiate the activity of molnupiravir (LagevrioTM) when combined with this drug.
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective
Control of the COVID-19 pandemic will require the use of pharmacological treatments against SARS-CoV2, and drugs that address the hyperinflammatory phase of the disease triggered by the so-called cytokine storm are particularly relevant.
Goodbye, 2021: a year of failures interspersed with remarkable triumphs
  • N. Talley
  • Political Science, Medicine
    The Medical journal of Australia
  • 2021
Overall, Australia has weathered the coronavirus disease 2019 (COVID19) pandemic remarkably well, thanks largely to the excellent public health response and our frontline health expertise, as well as
Open science policies of medical and health sciences journals before and during the COVID-19 pandemic: a repeat cross-sectional study
The COVID-19 pandemic has highlighted the importance of practising open science, however adherence to open science standards in audited policies was low overall, which may reduce progress in health and medical research.
The new normal? Redaction bias in biomedical science
It is demonstrated that the removal of a surprisingly small number of data points can be used to dramatically alter a result, and the impact of inappropriate redaction beyond a threshold value in biomedical science is formally quantified.


Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin, and the apparent safety and low cost suggest that iverMectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Ivermectin was investigated in 23 randomized clinical trials identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries and showed no significant effect on survival, time to clinical recovery, or duration of hospitalization.
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only.
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
Ivermectin as an adjunct reduces the rate of mortality, time of low O2 saturation, and duration of hospitalization in adult COVID-19 patients and the improvement of other clinical parameters shows that ivermECTin, with a wide margin of safety, had a high therapeutic effect on CO VID-19.
The guardian.
To persuade us to take seriously a bit of Bassey schmaltz after a non-stop exposition of hair-raising violence and uninhibited bisexuality is quite something, and shows the confidence of this amazing company under the direction of DV8's Nigel Charnock.
Open Forum Infectious Diseases 10.1093/ofid/ofab358 (2021)
  • 2021
The Guardian science/2021/jul/16/huge-study-supporting-ivermectinas-covid-treatment-withdrawn-over-ethical-concerns (16 July 2021)
  • 2021
Preprint at article/rs-100956/v3 (2020)
  • 2020